Environmental

IRTC’s R&D intensity near 10% of revenue supports product efficiency and lower resource waste, but peers in medtech often show similarly elevated innovation spend.

The company’s asset-light profile likely limits direct emissions exposure versus manufacturing-heavy peers, yet this advantage is common across digital health and diagnostics peers.

No provided evidence indicates material environmental controversies or regulatory breaches, leaving its environmental profile broadly in line with peers rather than distinctly superior.

Because environmental impacts are mostly indirect and peer norms are already relatively light, the company’s positioning is moderate rather than leading.

Social

High stock-based compensation at roughly 10% of revenue can support talent retention, but it also signals heavier dilution pressure than many established medtech peers.

Sustained R&D investment indicates continued focus on clinical utility and patient outcomes, which is supportive, though peers in innovative healthcare often show similar commitment.

As a healthcare technology provider, product reliability and data handling are material social factors, but no provided evidence shows a peer-leading record on these dimensions.

Overall social positioning appears balanced, with innovation and workforce incentives offset by compensation intensity that is not clearly better than peers.

Governance

Debt-to-equity of 3.9x and net debt-to-EBITDA of 23.9x indicate a more leveraged capital structure than many peers, increasing governance scrutiny around balance-sheet discipline.

Stock-based compensation above 10% of revenue suggests shareholder dilution risk, and peers with tighter compensation controls generally look stronger on capital allocation governance.

The absence of provided controversy data limits downside, but leverage and compensation intensity remain the most material governance weaknesses versus peers.

Taken together, governance is acceptable but not strong, because capital-allocation discipline appears weaker than in better-governed medtech comparables.

Overall Score

IRTC’s ESG profile is broadly middle-of-pack versus peers, with innovation and limited direct environmental exposure offset by weaker capital-allocation governance.

Score Driver: Elevated Leverage And Stock-Based Compensation Are The Main Factors Preventing A Stronger Relative ESG Score.